MC0704 is a STAT3 Inhibitor for Triple-negative Breast Cancer Research

By A Mystery Man Writer

MC0704 is a STAT3 inhibitor (IC50=2.13 μM), which can be used for the research of metastatic triple-negative breast cancer (mTNBC).

Small molecule agents for triple negative breast cancer: Current

Adagrasib (MRTX849), a Potent KRAS G12C Inhibitor for KRAS G12C-mutated Locally Advanced or Metastatic NSCLC Research

CX-5461 is an Orally Active rRNA Synthesis Inhibitor

COTI-2 is an Orally Available Mutant p53 Activator

Design, Synthesis, and Biological Activity of Marinacarboline

Inhibition of DOT1L enzyme activity by HSPA analogs and DOT1L

BI-0474 is a Potent KRAS G12C inhibitor

SP-146 is a Selective and non-ATP-Competitive Aurora B Inhibitor

KGP94 is a Selective Inhibitor of Cathepsin L for Cancer Research

BCI-215 is a Tumor Cell-Selective DUSP-MKP Inhibitor

Spiruchostatin A is a Potent HDAC Inhibitor with anticancer activity

FTI-2153 is a Highly Selective Farnesyltransferase Inhibitor

RETRACTED ARTICLE: A new synthetic derivative of cryptotanshinone

Multi-targeted kinase inhibition alleviates mTOR inhibitor

SAR-260301 is an Orally Active PI3Kβ Inhibitor for Melanoma